Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632205 | 0.89 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL17187860 | 0.80 | CYP1A2 (0.44) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL4584420 | 0.75 | MTNR1A (0.44) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL22967806 | 0.75 | CYP1A2 (0.52) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL12505926 | 0.72 | CYP1A2 (0.48) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL28873491 | 0.70 | TRPV1 (0.50) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL18428158 | 0.70 | MTNR1A (0.48) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL10850345 | 0.69 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL3328982 | 0.68 | MTNR1A (0.59) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL7921792 | 0.68 | MPL (0.54) | MTNR1AMTNR1BHTR2CHTR2BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137446-A1 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137446-A1 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MTNR1A, MTNR1B, AHR | MTNR1A 1/4885MTNR1B 2/4885HTR2C 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.